Clinical trials: Gastrointestinal Reflux
Gastroesophageal Reflux
Effect of Vecam 40/300 and Vecam 20/300 Compared to Omeprazole 20 mg on Gastric pH
The study is designed to assess and compare the effect of Vecam 40/300, Vecam 20/300 and Omeprazole 20 mg (a standard FDA approved GERD treatment) on the control of gastric pH.
- Trial name
- NCT00818870
- Testing
- Omeprazole, Vecam
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Vecta Ltd.
Gastroesophageal Reflux Disease
Epi-GERD Study: Epidemiological Evaluation in Patients With Gastro-Esophageal Reflux Disease (GERD)
Cross-sectional epidemiological study in patients with diagnosis of GERD (Gastroesophageal Reflux Disease) and with current treatment or with a history of recent treatment with some PPI (Proton Pump Inhibitor), in order to…
- Trial name
- Epi-ERGE (NCT04094402)
- Testing
- None. It is an observational study
- Where
- Colombia
- Volunteers
- 1,500 people
- Sponsor
- Scandinavia Pharma
Gastroesophageal Reflux Disease (GERD)
A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old
Gastroesophageal reflux disease (GERD) is caused by food or acid coming up from the stomach into the esophagus, repeatedly. The esophagus is the tube that carries food and liquids from the mouth to the stomach.
- Trial name
- NCT02616302
- Testing
- Dexlansoprazole
- Where
- 18 sites in United States, Canada and 3 more
- Volunteers
- 71 people
- Sponsor
- Takeda
Mitral Valve Regurgitation (Degenerative or Functional)
Edwards EVOQUE Eos MISCEND Study
Study to evaluate the safety and performance of the Edwards EVOQUE Eos mitral valve replacement system
- Trial name
- NCT02718001
- Testing
- Edwards EVOQUE Eos Mitral Valve Replacement System
- Where
- 19 sites in United States, Canada
- Volunteers
- 123 people
- Sponsor
- Edwards Lifesciences
GERD
Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients
To compare the efficacy of three different long-term treatment strategies of reflux disease in primary care setting.
- Trial name
- MAESTRO (NCT00444275)
- Testing
- esomeprazole (Nexium®), Xolaam®
- Where
- France
- Volunteers
- 3,029 people
- Sponsor
- AstraZeneca
Reflux Esophagitis
Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis
The purpose of the study is to investigate the efficacy and dose-effect relationship of X842 capsules at different dosages in the treatment of reflux esophagitis for 4 weeks in comparison with lansoprazole enteric-coated capsules.
- Trial name
- NCT04531475
- Testing
- X842, Lansoprazole
- Where
- 16 sites in China
- Volunteers
- 90 people
- Sponsor
- Jiangsu Sinorda Biomedicine Co., Ltd
Gastroesophageal Reflux Disease
Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab
This observational study is a large-scale, prospective, and multi-institutional observational study. Patients from 19 to 75 years of age, will take a self-assessment (PRO) during the study period before and after administration…
- Trial name
- NCT05614752
- Testing
- Fexuprazan
- Where
- South Korea
- Volunteers
- 10,067 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
GERD, Gastroesophageal Reflux Disease
LINX Reflux Management System in Subjects With GERD Who Have Previously Undergone a Laparoscopic Sleeve Gastrectomy
The purpose of this study is to evaluate the LINX device in patients who have previously undergone laparoscopic sleeve gastrectomy (LSG) for obesity and have chronic gastroesophageal reflux disease (GERD).
- Trial name
- RELIEF (NCT02429830)
- Testing
- LINX device
- Where
- 12 sites in United States
- Volunteers
- 30 people
- Sponsor
- Torax Medical Incorporated
Gastroesophageal Reflux Disease (GERD)
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to determine the safety and efficacy of Rabeprazole extended release (ER) 50 mg versus Esomeprazole 40 mg for healing and symptomatic relief among subjects with erosive gastroesophageal reflux disease…
- Trial name
- NCT00658528
- Testing
- Rabeprazole sodium, Esomeprazole
- Where
- 88 sites in United States, Argentina and 11 more
- Volunteers
- 1,061 people
- Sponsor
- Eisai Inc.
Erosive Gastroesophageal Reflux Disease, Non-Erosive Reflux Disease
Efficacy of Pantoprazole in Patients Older Than 12 Years With Reflux Associated Sleep Disorders (PULS)
The aim of the study was to evaluate the effect of Pantoprazole 20 mg/40 mg for 14 days on symptoms in patients with NERD (non-erosive reflux disease) or eGERD (erosive gastroesophageal reflux disease) with special focus on the…
- Trial name
- PULS (NCT00562094)
- Testing
- Pantoprazole
- Where
- 1,153 sites in Germany
- Volunteers
- 8,616 people
- Sponsor
- Nycomed
Gastroesophageal Reflux Disease
An Observational Clinical Feasibility Study of the Magnetic Esophageal Sphincter
Magnetic Esophageal Sphincter implant is intended to reinforce Esophageal Sphincter function in the treatment of Gastroesophageal Reflux Disease (GERD)
- Trial name
- NCT01058070
- Testing
- Torax Medical, Inc. LINX Reflux Management System
- Where
- 5 sites in United States, Italy and 1 more
- Volunteers
- 44 people
- Sponsor
- Torax Medical Incorporated
Gastro-esophageal Reflux Disease
Outcomes for Patients With Gastro-Esophageal Reflux Disease
Gastro-esophageal reflux disease (GERD), the most common cause of erosive esophagitis (EE), remains highly prevalent worldwide. GERD poses substantial burden on both patients and society.
- Trial name
- NCT03824548
- Testing
- this is non-intervention study, there is no intervention drug or device in this study.
- Where
- China
- Volunteers
- 50,000 people
- Sponsor
- Tianjin Happy Life Technology Co., Ltd.
GERD, Acid Reflux, Treatment
Omega Cuff for GERD Feasibility Study
This clinical feasibility study is to evaluate the performance of the Omega-Cuff in the treatment of acid reflux for up to 15 patients with a 1-year follow-up period.
- Trial name
- NCT04793035
- Testing
- Omega-Cuff
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Aplos Medical
Gastroesophageal Reflux Disease, Erosive Esophagitis
Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets
The purpose of this study is to measure the in-vivo disintegration time of a single dexlansoprazole delayed-release orally disintegrating (OD) tablet.
- Conditions
- Gastroesophageal Reflux Disease, Erosive Esophagitis, Heartburn
- Trial name
- NCT02096458
- Testing
- Dexlansoprazole
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Takeda
GERD
Structured Treatment of Gastroesophageal Reflux in a Company Health Care Setting, -Effect on Quality of Life, Symptoms and Productivity
The study aims to evaluate if a GERD treatment programme, in accordance with current regional recommendations, in a company health care setting, has an impact on health related quality of life (HRQoL), symptoms, and productivity…
- Trial name
- NCT00884247
- Where
- Sweden
- Volunteers
- 36 people
- Sponsor
- AstraZeneca
Erosive Reflux Disease, Heartburn
Observationa Study is a Prospective and Multi-institutional Observational Study.
This observational study is a prospective, multi-institutional non intervention study to examine the prescription patterns, corresponding treatment effects and safety in routine clinical practice for patients prescribed for the…
- Conditions
- Erosive Reflux Disease, Heartburn, Acid Regurgitation
- Trial name
- NCT06952855
- Where
- South Korea
- Volunteers
- 5,536 people
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
GERD
PPI Test in GP Patients
The purpose of this study is to determine the diagnostic value of two week treatment with Nexium as a confirmatory test for patients with suspected reflux disease.
- Trial name
- NCT00318084
- Testing
- Esomeprazole, Ambulatory 24-hour esophageal pH-monitoring
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease (GERD)
Post-Market Registry for the Evaluation of RefluxStop in GERD Treatment
This post-market registry aims to assess safety and performance of RefluxStop™ in the treatment of Gastroesophageal Reflux Disease (GERD) in standard of care procedures.
- Trial name
- NCT05870163
- Testing
- RefluxStop implantation, Nissen fundoplication
- Where
- 6 sites in Germany, Italy and 2 more
- Volunteers
- 2,500 people
- Sponsor
- Implantica CE Reflux Ltd.
Gastroesophageal Reflux Disease
A Study to Evaluate the Effect of Lansoprazole on Infants With Gastroesophageal Reflux Disease.
The purpose of this study is to understand how quickly lansoprazole, once daily (QD), improves feeding in premature babies or babies less than 28 days of age.
- Trial name
- NCT00220818
- Testing
- Lansoprazole
- Volunteers
- 24 people
- Sponsor
- Takeda
GERD
Canadian, Multi-Centre Study of Symptom Burden and Clinical Management in Subjects With GERD
This is a cross-sectional study of symptom burden and clinical management. A subset of patients who have attended the Primary Care (PC) office with reflux symptoms during a retrospective period of 4 months (Index Visit) are…
- Trial name
- RANGE (NCT00634023)
- Where
- 15 sites in Canada
- Volunteers
- 500 people
- Sponsor
- AstraZeneca